ReviewFrontiers in pharmacology2020
Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.International journal of clinical pharmacy · 2026Article
- Tailored Therapeutic Strategies for Fetuses, Neonates, Pediatrics, Geriatrics, Athletes, and Critical Cases in the Era of Personalized Medicine.Diseases (Basel, Switzerland) · 2025Review
- Comparative analysis of Mycoplasma Pneumoniae and Drug-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Children.Pakistan journal of medical sciences · 2025Article
- Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice.Frontiers in pharmacology · 2025Review
- Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.Frontiers in medicine · 2025Article
- Scoping review of enablers and challenges of implementing pharmacogenomics testing in the primary care settings.BMJ open · 2024Article
- ALDRESS: A Retrospective Pilot Study to Develop a Pharmacological Causality Algorithm for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).Journal of clinical medicine · 2024Article
- Severe cutaneous adverse reactions.Nature reviews. Disease primers · 2024Review
- Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products.Genes · 2024Review
- Tools for Etiologic Diagnosis of Drug-Induced Allergic Conditions.International journal of molecular sciences · 2023Review
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review.Frontiers in medicine · 2023Review
- A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations.Frontiers in genetics · 2023Article
- Pharmacogenomic landscape of Indian population using whole genomes.Clinical and translational science · 2022Article
- The important role of non-covalent drug-protein interactions in drug hypersensitivity reactions.Allergy · 2022Review
- Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.Frontiers in medicine · 2022Article
- An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.Frontiers in pharmacology · 2022Review
- Allopurinol-Induced Stevens-Johnson Syndrome in Javanese Men With Positive HLA-B*58:01.Frontiers in genetics · 2022Article
- Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over 30%, thus causing a major burden on the healthcare system. Recent pharmacogenomic studies have revealed strong associations between SCAR and the genes encoding human-leukocyte antigens (HLAs) or drug-metabolizing enzymes. Some of pharmacogenetic markers have been successfully applied in clinical practice to protect patients from SCAR, such as HLA-B*15:02 and HLA-A*31:01 for new users of carbamazepine, HLA-B*58:01 for allopurinol, and HLA-B*57:01 for abacavir. This article aims to update the current knowledge in the field of pharmacogenomics of drug hypersensitivities or SCAR, and its implementation in the clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.